[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100371694":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":40,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Study Population",null,"Adult patients with a diagnosis of cancer receiving checkpoint inhibitor therapy at the University of Pennsylvania's Abramson Cancer Center (ACC).",[13],{"name":14,"affiliation":15,"role":16},"Sokratis Apostolidis, MD","University of Pennsylvania","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Kyra J Sacksith","CONTACT","215-898-9339","kyra.sacksith@pennmedicine.upenn.edu",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"University of Pennsylvania - Abramson Cancer Center","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-75.16362,39.95238,{"lat":36,"lon":35},[39],{"name":19,"role":20,"phone":10,"phoneExt":10,"email":10},{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100371694","autoimmunity-after-checkpoint-blockade-100371694",false,"NCT04119713","Autoimmunity After Checkpoint Blockade","Mechanisms of Immunotoxicology in Cancer Patients","Inclusion Criteria:\n\n* A diagnosis of cancer and prescription for a checkpoint inhibitor\n\nExclusion Criteria:\n\n* Any subjects not willing or able to give consent\n* Children under the age of 18\n* A history of transplant","ALL","18 Years",{"count":52,"type":53},600,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).",[57,58,59,60],"Autoimmunity","Cancer","Immunotoxicity","Oncology","2026-01-07",{"date":63,"type":64},"2026-01-08","ACTUAL",{"date":66,"type":64},"2020-02-24",{"date":68,"type":53},"2026-06-30",{"name":5,"class":6},1]